Question · Q3 2025
Thomas Trimarchi, on behalf of Martin Oster, asked for more details on the serious treatment-related adverse events (TEAEs) observed with Encalirate in periods two and three of its trial, and on standard of care in period one.
Answer
Neil Kumar, CEO and Founder, BridgeBio Pharma, clarified that the serious TEAEs were related to hypercalcemia. He noted that hypercalcemia on standard of care was quite high, requiring hospitalization, while Encalirate-related hypercalcemia was much milder, with the patient hospitalized for unrelated issues (altered mental status and UTI) and subsequently dosed down without discontinuation. Kumar emphasized that Encalirate led to fewer discontinuations than standard of care, highlighting its safety due to its precise allosteric mechanism.